OGA INHIBITOR COMPOUNDS
The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatmen...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | MARTINEZ-VITURRO, Carlos Manuel CONDE-CEIDE, Susana VEGA RAMIRO, Juan DELGADO-JIMÉNEZ, Francisca BARTOLOMÉ-NEBREDA, José Manuel TRABANCO-SUÁREZ, Andrés |
| description | The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.
La présente invention concerne des inhibiteurs d'O-GlcNAc hydrolase (OGA). L'invention concerne également des compositions pharmaceutiques comprenant de tels composés, des procédés de préparation de tels composés et compositions, et l'utilisation de tels composés et compositions pour la prévention et le traitement de troubles dans lesquels l'inhibition de l'OGA est bénéfique, telles que des tauopathies, en particulier la maladie d'Alzheimer ou la paralysie supranucléaire progressive ; et des maladies neurodégénératives accompagnées d'une pathologie tau, en particulier la sclérose latérale amyotrophique ou la démence du lobe fronto-temporale provoquée par des mutations C90RF72. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2019243527A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2019243527A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2019243527A13</originalsourceid><addsrcrecordid>eNrjZBD3d3dU8PTz8HTyDPEPUnD29w3wD_VzCeZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGhpZGJsamRuaOhsbEqQIAVV4gaw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>OGA INHIBITOR COMPOUNDS</title><source>esp@cenet</source><creator>MARTINEZ-VITURRO, Carlos Manuel ; CONDE-CEIDE, Susana ; VEGA RAMIRO, Juan ; DELGADO-JIMÉNEZ, Francisca ; BARTOLOMÉ-NEBREDA, José Manuel ; TRABANCO-SUÁREZ, Andrés</creator><creatorcontrib>MARTINEZ-VITURRO, Carlos Manuel ; CONDE-CEIDE, Susana ; VEGA RAMIRO, Juan ; DELGADO-JIMÉNEZ, Francisca ; BARTOLOMÉ-NEBREDA, José Manuel ; TRABANCO-SUÁREZ, Andrés</creatorcontrib><description>The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.
La présente invention concerne des inhibiteurs d'O-GlcNAc hydrolase (OGA). L'invention concerne également des compositions pharmaceutiques comprenant de tels composés, des procédés de préparation de tels composés et compositions, et l'utilisation de tels composés et compositions pour la prévention et le traitement de troubles dans lesquels l'inhibition de l'OGA est bénéfique, telles que des tauopathies, en particulier la maladie d'Alzheimer ou la paralysie supranucléaire progressive ; et des maladies neurodégénératives accompagnées d'une pathologie tau, en particulier la sclérose latérale amyotrophique ou la démence du lobe fronto-temporale provoquée par des mutations C90RF72.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20191226&DB=EPODOC&CC=WO&NR=2019243527A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20191226&DB=EPODOC&CC=WO&NR=2019243527A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MARTINEZ-VITURRO, Carlos Manuel</creatorcontrib><creatorcontrib>CONDE-CEIDE, Susana</creatorcontrib><creatorcontrib>VEGA RAMIRO, Juan</creatorcontrib><creatorcontrib>DELGADO-JIMÉNEZ, Francisca</creatorcontrib><creatorcontrib>BARTOLOMÉ-NEBREDA, José Manuel</creatorcontrib><creatorcontrib>TRABANCO-SUÁREZ, Andrés</creatorcontrib><title>OGA INHIBITOR COMPOUNDS</title><description>The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.
La présente invention concerne des inhibiteurs d'O-GlcNAc hydrolase (OGA). L'invention concerne également des compositions pharmaceutiques comprenant de tels composés, des procédés de préparation de tels composés et compositions, et l'utilisation de tels composés et compositions pour la prévention et le traitement de troubles dans lesquels l'inhibition de l'OGA est bénéfique, telles que des tauopathies, en particulier la maladie d'Alzheimer ou la paralysie supranucléaire progressive ; et des maladies neurodégénératives accompagnées d'une pathologie tau, en particulier la sclérose latérale amyotrophique ou la démence du lobe fronto-temporale provoquée par des mutations C90RF72.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZBD3d3dU8PTz8HTyDPEPUnD29w3wD_VzCeZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGhpZGJsamRuaOhsbEqQIAVV4gaw</recordid><startdate>20191226</startdate><enddate>20191226</enddate><creator>MARTINEZ-VITURRO, Carlos Manuel</creator><creator>CONDE-CEIDE, Susana</creator><creator>VEGA RAMIRO, Juan</creator><creator>DELGADO-JIMÉNEZ, Francisca</creator><creator>BARTOLOMÉ-NEBREDA, José Manuel</creator><creator>TRABANCO-SUÁREZ, Andrés</creator><scope>EVB</scope></search><sort><creationdate>20191226</creationdate><title>OGA INHIBITOR COMPOUNDS</title><author>MARTINEZ-VITURRO, Carlos Manuel ; CONDE-CEIDE, Susana ; VEGA RAMIRO, Juan ; DELGADO-JIMÉNEZ, Francisca ; BARTOLOMÉ-NEBREDA, José Manuel ; TRABANCO-SUÁREZ, Andrés</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2019243527A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2019</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>MARTINEZ-VITURRO, Carlos Manuel</creatorcontrib><creatorcontrib>CONDE-CEIDE, Susana</creatorcontrib><creatorcontrib>VEGA RAMIRO, Juan</creatorcontrib><creatorcontrib>DELGADO-JIMÉNEZ, Francisca</creatorcontrib><creatorcontrib>BARTOLOMÉ-NEBREDA, José Manuel</creatorcontrib><creatorcontrib>TRABANCO-SUÁREZ, Andrés</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MARTINEZ-VITURRO, Carlos Manuel</au><au>CONDE-CEIDE, Susana</au><au>VEGA RAMIRO, Juan</au><au>DELGADO-JIMÉNEZ, Francisca</au><au>BARTOLOMÉ-NEBREDA, José Manuel</au><au>TRABANCO-SUÁREZ, Andrés</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>OGA INHIBITOR COMPOUNDS</title><date>2019-12-26</date><risdate>2019</risdate><abstract>The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.
La présente invention concerne des inhibiteurs d'O-GlcNAc hydrolase (OGA). L'invention concerne également des compositions pharmaceutiques comprenant de tels composés, des procédés de préparation de tels composés et compositions, et l'utilisation de tels composés et compositions pour la prévention et le traitement de troubles dans lesquels l'inhibition de l'OGA est bénéfique, telles que des tauopathies, en particulier la maladie d'Alzheimer ou la paralysie supranucléaire progressive ; et des maladies neurodégénératives accompagnées d'une pathologie tau, en particulier la sclérose latérale amyotrophique ou la démence du lobe fronto-temporale provoquée par des mutations C90RF72.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2019243527A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | OGA INHIBITOR COMPOUNDS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A24%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MARTINEZ-VITURRO,%20Carlos%20Manuel&rft.date=2019-12-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2019243527A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |